Pfizer invests in French gene therapy co.
Pfizer announced it has acquired a 15 percent stake in Vivet Therapeutics, with an exclusive option to fully acquire the privately-held French gene therapy company. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 20, 2019 Category: Pharmaceuticals Source Type: news

Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China
Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. (Source: World Pharma News)
Source: World Pharma News - March 19, 2019 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

With single gene insertion, blind mice regain sight
(University of California - Berkeley) People left blind by retinal degeneration have one option: electronic eye implants. UC Berkeley neuroscientists have developed an alternative: gene therapy that, in tests, restored vision in blind mice. A gene for green opsin delivered via virus gave blind mice enough sight to discern patterns on an iPad at a resolution sufficient for humans to read. Given existing AAV eye therapies already approved, this new therapy could be ready for clinical trials in three years. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 15, 2019 Category: Biology Source Type: news

Call For CRISPR Moratorium Echoes Early Days Of Gene Therapy
Notable group of international scientists have issued a call to adopt a moratorium on CRISPR heritable genome editing in the wake of the Chinese edited baby debacle. The move echoes the history of gene therapy which also had self-imposed bans and strict guidelines. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 14, 2019 Category: Pharmaceuticals Authors: Greg Licholai, Contributor Source Type: news

Therapy could improve and prolong sight in those suffering vision loss
(University of California - Berkeley) Ganglion cells in the eye generate noise as the light-sensitive photoreceptors die in diseases such as retinitis pigmentosa. Now, UC Berkeley neurobiologists have found a drug and gene therapy that can tamp down the noise, improving sight in mice with RP. These therapies could potentially extend the period of useful vision in those with degenerative eye diseases, including, perhaps, age-related macular degeneration. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 13, 2019 Category: Biology Source Type: news

International congress of Myology 2019
(AFM-T é l é thon) Twenty years after the first International Congress of Myology in March 2000, the first innovative drugs (gene therapy, ...) are available to patients, the number of clinical trials grows around the world, involving hundreds of patients. Myology, this little-known science dedicated to the study of muscles, is, today, one of the big therapeutic innovation field. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 12, 2019 Category: International Medicine & Public Health Source Type: news

First sickle cell patient to get gene therapy is symptom-free after 9 months
Manny Johnson, 21, was treated for sickle cell disease with an experimental gene therapy to stop his body from making faulty blood cells. Nine months later, he is symptom free. (Source: the Mail online | Health)
Source: the Mail online | Health - March 11, 2019 Category: Consumer Health News Source Type: news

Sickle cell anemia patients react to breakthrough treatment
A cutting-edge clinical trial made a breakthrough in its effort to cure sickle cell anemia. The painful genetic disease affects about 100,000 Americans every year, mostly African Americans. On "60 Minutes," Dr. Jon LaPook followed Jenelle Stephenson for more than a year as she underwent an innovative kind of gene therapy at the National Institutes of Health. The therapy uses HIV to treat patients, but the virus is weakened, so it cannot cause AIDS. LaPook, who watched his report Sunday night with four sickle cell anemia patients, and Stephenson join "CBS This Morning" to discuss the remarkable trial res...
Source: Health News: CBSNews.com - March 11, 2019 Category: Consumer Health News Source Type: news

NIH renews $13M contract with Penn's gene therapy program
The National Institutes of Health has once again renewed a five-year contract with the University of Pennsylvania's gene therapy program, which will receive $13 million to support the advancement of gene-therapy research to the clinic. The contract was awarded by National Heart, Lung and Blood Institute to what operates as the Gene Therapy Program Preclinical Vector Core in the Perelman School of Medicine at Penn. The contract will support the preclinical vector production, analytics, and immunology… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 7, 2019 Category: Health Management Authors: John George Source Type: news

NIH renews $13M contract with Penn's gene therapy program
The National Institutes of Health has once again renewed a five-year contract with the University of Pennsylvania's gene therapy program, which will receive $13 million to support the advancement of gene-therapy research to the clinic. The contract was awarded by National Heart, Lung and Blood Institute to what operates as the Gene Therapy Program Preclinical Vector Core in the Perelman School of Medicine at Penn. The contract will support the preclinical vector production, analytics, and immunology… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 7, 2019 Category: Biotechnology Authors: John George Source Type: news

Scientists find method to boost CRISPR efficiency
(UT Southwestern Medical Center) Scientists have developed a method to boost the efficiency of CRISPR gene editing in Duchenne muscular dystrophy (DMD), according to a study that could have implications for optimizing gene therapies for other diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2019 Category: International Medicine & Public Health Source Type: news

Biogen to buy gene therapy co focused on rare eye disease
Biogen has agreed to buy British gene-therapy company Nightstar Therapeutics, accelerating Biogen's entry into the emerging growth area of eye diseases. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 4, 2019 Category: Pharmaceuticals Source Type: news

Biogen deviates from neuroscience drugs with $800M acquisition
Biogen is expanding its portfolio outside of neuroscience, announcing Monday it is purchasing a British biotech firm focused on retinal disorders for $800 million. Biogen (Nasdaq: BIIB) is acquiring clinical stage gene therapy company Nightstar Therapeutics (Nasdaq: NITE), which is developing treatments for multiple retinal disorders. Its lead candidate, a treatment for a rare hereditary eye disorder that leads to blindness, is currently being tested in a Ph ase 3 trial. The deal is expected to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 4, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news

Nationwide Children's gene therapy spinoff acquired for $165M after promising results
A third gene therapy spinoff from Nationwide Children's Hospital has been acquired, this time for $165 million. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 28, 2019 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news

Gene therapy trials point to cure for rare liver disease
EU-funded researchers are close to developing a cure for Crigler-Najjar syndrome, an extremely rare, life-threatening liver disease. The groundbreaking research, currently being validated in clinical trials, could also pave the way for the treatment of other genetic disorders. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - February 27, 2019 Category: Research Source Type: news

N.J. biotech firm expanding to Philadelphia, creating 200 new jobs
In another boost to Philadelphia ’s standing as a cell and gene therapy hub, Cranbury, New Jersey-based Amicus Therapeutics said Tuesday it is establishing a new global research and gene therapy center at uCity Square, where the company expects to have 200 employees over the next few years. Amicus will occupy the top three floor s — a total of 75,000-square-foot — at the new University City Science Center building at 3675 Market Street. Its research center is expected to be completed during… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 26, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Roche to buy Spark Therapeutics
Roche Holding has entered a definitive merger agreement with Spark Therapeutics, as the Swiss drugmaker seeks to expand its ability to treat rare diseases through gene therapies, as well as build its hemophilia portfolio. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 25, 2019 Category: Pharmaceuticals Source Type: news

GE/Roche/Spark: flair for genes
Deal may turn Swiss group from a laggard into a leader in gene therapy (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 25, 2019 Category: Pharmaceuticals Source Type: news

Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Gracell addresses the issues of complex manufacture and high cost of cellular gene therapeutics SUZHOU and SHANGHAI, China, Feb. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Gracell Biotechnologies, Co., Ltd. ("Gracell") announced th... Biopharmaceuticals, Venture Capital Gracell Biotechnologies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 25, 2019 Category: Pharmaceuticals Source Type: news

Roche 'steps up' for gene therapy with $4.3 billion Spark bet
Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to "step up", Chief Executive Severin Schwan said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche bets $4.3 billion on Spark in gene therapy move
Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche to buy gene therapy specialist Spark in $4.3 billion deal
Roche Holding AG said on Monday it will buy Spark Therapeutics in a $4.3 billion deal, as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Report: Pharmaceutical giant close to deal for Philadelphia's Spark Therapeutics
Roche Holding AG is close to a deal to buy Philadelphia-based Spark Therapeutics for nearly $5 billion, the Wall Street Journal is reporting. Citing sources familiar with the deal, the Journal reports that it could be announced "on Monday if not sooner." If the deal goes through, Roche would be paying a huge premium for the gene therapy company Spark, whose market value was about $2 billion when the markets closed on Friday. The Journa l reported that another company was involved in the bidding… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 23, 2019 Category: Biotechnology Authors: Craig Ey Source Type: news

Report: Pharmaceutical giant close to deal for Philadelphia's Spark Therapeutics
Roche Holding AG is close to a deal to buy Philadelphia-based Spark Therapeutics for nearly $5 billion, the Wall Street Journal is reporting. Citing sources familiar with the deal, the Journal reports that it could be announced "on Monday if not sooner." If the deal goes through, Roche would be paying a huge premium for the gene therapy company Spark, whose market value was about $2 billion when the markets closed on Friday. The Journa l reported that another company was involved in the bidding… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 23, 2019 Category: Pharmaceuticals Authors: Craig Ey Source Type: news

Novartis gene therapy would be cost effective up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis gene therapy would be cost effective up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis gene therapy is cost effective at up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 to $900,000, according an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Voyager Therapeutics stock jumps on 2nd Parkinson's deal
Cambridge startup Voyager Theraupetics ’ stock shot up nearly 25 percent Friday after it announced a second partnership deal with AbbVie to develop gene therapies for Parkinson’s disease.  Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (NYSE: ABBV), launching a research effort to develop anti body treatments that can be delivered directly to the brain and target a protein called alpha-synuclein that has been linked to Parkinson's. AbbVie is paying the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 22, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Inside Spark's quest to set the standards for gene therapy payments
Rebates are already part of the process. Installment payments could be next for expensive gene therapy products. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 22, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Gene therapy in the womb could cure rare brain disorder that causes seizures, memory loss
Using the gene-editing technology CRISPR, scientists at the University of North Carolina switched on a muted gene in mice embryos, which were then born with no trace of the disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2019 Category: Consumer Health News Source Type: news

Sales of Philadelphia-born gene therapy product hit $27M during first year
In its first year, Luxturna — the first Food and Drug Administrative-approved gene therapy treatment for an inherited disease — generated $27 million in sales for Philadelphia-based Spark Therapeutics. Spark said it has shipped 75 vials of Luxturna, a one-time gene therapy used to treat adult and pediatric patients with v ision loss caused by inherited retinal dystrophy from a genetic mutation. The inherited retinal disorder, which leads to blindness if untreated, afflicts an estimated 1,000… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 19, 2019 Category: American Health Authors: John George Source Type: news

Novartis-owned firm picks Durham over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The company plans to invest $60 million by December 31, 2020. To receive incentives, the firm will be required to keep the 200 employees it already has in Durham, at a site established last year to develop treat ments for rare and orphan neurological genetic… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 19, 2019 Category: Health Management Authors: Lauren Ohnesorge Source Type: news

Putting the brakes on aging
(Salk Institute) Salk Institute researchers have developed a new gene therapy to help decelerate the aging process. The findings, published on February 18, 2019, in the journal Nature Medicine, highlight a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome, a rare genetic disorder that also afflicts humans. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 19, 2019 Category: International Medicine & Public Health Source Type: news

Alliance for Cancer Gene Therapy honors cancer pioneer Dr. Carl June at April 18 Gala
(Alliance for Cancer Gene Therapy) ACGT to honor cancer gene therapy pioneer Dr. Carl June with The Edward Netter Leadership Award on April 18 in New York City. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2019 Category: Cancer & Oncology Source Type: news

Gene therapy hopes for AMD
Oxford woman in world first trials of treatment to prevent sight loss Related items fromOnMedica Genetic risk model could guide prostate cancer screening Age itself is not a risk factor for complications after surgery among older patients Two out of three hospital eye units reliant on locums to fill senior doctor posts A&E dementia admissions soar due to 'threadbare' social care Tackle continuing eye care crisis now, royal college urges Hunt (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 19, 2019 Category: UK Health Source Type: news

Gene therapy could treat rare brain disorder in unborn babies
Doctors could use Crispr tool to inject benign virus into foetus ’s brain to ‘switch on’ key genesScientists are developing a radical form ofgene therapy that could cure a devastating medical disorder by mending mutations in the brains of foetuses in the womb.The treatment, which has never been attempted before, would involve doctors injecting the feotus ’s brain with a harmless virus that infects the neurons and delivers a suite of molecules that correct the genetic faults.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 18, 2019 Category: Science Authors: Ian Sample Science editor Tags: Gene editing Neuroscience Genetics Ethics Health Society World news Biology Source Type: news

Scientists launch first attempt to halt most common cause of age-related blindness with gene therapy
Surgeons at Oxford University have launched their first attempt at halting age-related macular degeneration, which is the most common cause of blindness and affects 600,000 people in the UK. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2019 Category: Consumer Health News Source Type: news

Novartis-owned firm picks NC over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The company plans to invest $60 million by December 31, 2020. To receive incentives, the firm will be required to keep the 200 employees it already has in Durham, at a site established last year to develop treat ments for rare and orphan neurological genetic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 18, 2019 Category: Biotechnology Authors: Lauren Ohnesorge Source Type: news

Novartis-owned firm picks NC over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The company plans to invest $60 million by December 31, 2020. To receive incentives, the firm will be required to keep the 200 employees it already has in Durham, at a site established last year to develop treat ments for rare and orphan neurological genetic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 18, 2019 Category: Pharmaceuticals Authors: Lauren Ohnesorge Source Type: news

Novartis-owned firm picks Durham over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The company plans to invest $60 million by December 31, 2020. To receive incentives, the firm will be required to keep the 200 employees it already has in Durham, at a site established last year to develop treat ments for rare and orphan neurological genetic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 18, 2019 Category: Biotechnology Authors: Lauren Ohnesorge Source Type: news

Novartis-owned firm picks Durham over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The company plans to invest $60 million by December 31, 2020. To receive incentives, the firm will be required to keep the 200 employees it already has in Durham, at a site established last year to develop treat ments for rare and orphan neurological genetic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 18, 2019 Category: Pharmaceuticals Authors: Lauren Ohnesorge Source Type: news

Ocugen wins orphan drug status for ocular gene therapy
The FDA has given Ocugen orphan drug status for a gene therapy designed to treat NR2E3 mutation-associated retinal degenerative disease. The Malvern, Penn.-based company’s OCU400 product includes an adeno-associated virum serotype 5 capsid that contains the gene for human nuclear hormone receptor NR2E3. Get the full story at our sister site, Drug Delivery Business News. The post Ocugen wins orphan drug status for ocular gene therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance ocugen Source Type: news

Historic Change Imminent in Food Allergy, Asthma Treatments Historic Change Imminent in Food Allergy, Asthma Treatments
Biologics, gene therapy, alterations to the microbiome, and immunotherapy are all dramatically changing the way allergy and asthma will be treated.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2019 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

UniQure gene therapy shows promising result in mid-stage trial
Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

UniQure gene therapy shows rise in blood-clotting protein levels
Drug developer UniQure NV said on Friday its gene therapy to treat hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a small study. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

UniQure gene therapy shows rise in blood-clotting protein in trial
UniQure NV said on Friday its gene therapy to treat patients with a blood disorder, hemophilia B, increased the levels of a protein that helps in blood clotting after 12 weeks. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Researchers Are Working on a Surprising Way to Deliver Insulin Without an Injection: Swallowing the Needle
Needles aren’t popular. For people with type 1 diabetes (and some with type 2 diabetes) that can be a problem, since treatment requires regular injections with insulin. Now, researchers at MIT have come up with a novel way to one day eliminate the need for injections: with a tiny swallowable device that can automatically inject insulin directly into the stomach wall. In a report published in Science, Robert Langer and Giovanni Traverso describe what they call a self-orienting millimeter scale applicator, or SOMA, that they developed to make injecting drugs easier. So far, SOMA has only been tested in animals. Roughly...
Source: TIME: Health - February 7, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized diabetes healthytime Source Type: news

Gene therapy stocks plunge after poor trial data
Shares of U.S. gene therapy companies sank on Thursday after drugs developed by two small firms failed to show promise in separate clinical trials, underscoring the challenges in an emerging, lucrative field of biotech. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Nanomachines are taught to fight cancer
(ITMO University) Scientists from ITMO University in collaboration with their international colleagues proposed new DNA-based nanomachines that can be used for gene therapy of cancer. This new invention can greatly contribute to making the treatment of oncological diseases more effective and selective. The results were published in Angewandte Chemie. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2019 Category: Cancer & Oncology Source Type: news

Gene therapy against chlamydia to prevent infection shows promise
The most common sexually transmitted disease in the world may have finally met its match, as researchers say they developed a treatment to prevent chlamydia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 6, 2019 Category: Consumer Health News Source Type: news